



**Vaccines and Global Health: The Week in Review**  
**08 February 2025 :: Issue 785**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

## ***Milestones, Perspectives***

.....  
.....

### **WHO Executive Board**

#### **156th session of the Executive Board**

**3–11 February 2025.**

The Executive Board is composed of 34 technically qualified members elected for three-year terms. The main functions of the Board are to implement the decisions and policies of the Health Assembly, and to advise and generally facilitate its work.

***Watch the Executive Board sessions [here](#)***

#### **Main Documents**

*Agenda and Supporting Reports, Documents*

#### **Resolutions**

[EB156.R1](#) Expression of appreciation to Dr Matshidiso Moeti

[EB156.R2](#) Appointment of the Regional Director for Europe

[EB156.R3](#) Health conditions in the occupied Palestinian territory, including east Jerusalem

#### **News**

**WHO's Executive Board discusses health topics of interest to all**

3 February 2025 *Departmental update*

#### **Speeches**

**WHO Director-General's congratulatory remarks for the re-election of RD Hans Kluge – 4 February 2025**

**WHO Director-General's opening remarks at the farewell remarks for outgoing Regional Director Moeti – 4 February 2025**

**WHO Director-General's opening remarks at the 156th session of the Executive Board – 3 February 2025**

*[Excerpt]*

...Honourable ministers, dear colleagues and friends,

**As you know, two weeks ago, President Donald Trump signed an Executive Order announcing his intention to withdraw the United States from WHO. We regret the decision, and we hope the US will reconsider.** We would welcome constructive dialogue to preserve and strengthen the historic relationship between WHO and the USA that helped bring significant impacts like the eradication of smallpox - I can give you a long list.

**The Executive Order gave four reasons for the decision to withdraw from WHO. First, it says that WHO has “failed to adopt urgently needed reforms”.**

As this Board is aware, over the course of the past seven years, under the guidance and governance of Member States, WHO has implemented the deepest and most wide-ranging reforms in the Organization's history.

The WHO Transformation has touched every part of our work: our strategy, operating model, processes, partnerships, financing, workforce and culture.

We have also taken action on the recommendations of the Agile Member States Task Group; We have implemented 85 of the 97 reforms proposed in the Secretariat Implementation Plan on reform; And we are implementing the recommendations of the Action for Results Group, led by WHO Representatives, to strengthen our country offices.

For us, change is a constant, and that's what our Member States told us when we started the reform, "change is a constant". We believe in continuous improvement, and we would welcome suggestions from the United States and all Member States for how we can serve you and the people of the world better. So, although we are doing a lot of reform, additional is welcome.

### **Second, the order says that WHO "demands unfairly onerous payments from the US, out of proportion with what other countries contribute".**

Member States understand how assessed contributions are calculated, and you know that some countries choose to make higher voluntary contributions than others.

Addressing the imbalance between assessed and voluntary contributions, and reducing WHO's over-reliance on a handful of traditional donors, has been one of the major areas of our Transformation. Because when we started the Transformation, the reliance on a few traditional donors was identified as a risk. And we have decided then, seven years ago, to broaden the donor base.

Last week the PBAC recommended the next 20% increase in assessed contributions, and we ask this Board to endorse that recommendation.

This is a critical element of our long-term plan to broaden our donor base, and will over the long term reduce the burden of financing for traditional donors, including the U.S.

We therefore continue to seek the support and engagement of all Member States, including the U.S., for our shared vision to put WHO on a more sustainable financial footing.

### **Third, the order refers to WHO's alleged "mishandling of the COVID-19 pandemic and other global health crises".**

Last week marked five years since I declared a public health emergency of international concern, on the 30<sup>th</sup> of January 2020. At the time, outside of China there were fewer than 100 reported cases, and no reported deaths.

On New Year's Eve 2019 and New Year's Day 2020, when much of the world was on holiday, WHO was not.

From the moment we picked up the first signals of "viral pneumonia" in Wuhan, we asked for more information, activated our emergency incident management system, alerted the world, convened global experts, and published comprehensive guidance for countries on how to protect their populations and health systems – all before the first death from this new disease was reported in China on the 11th of January 2020.

Of course there would be challenges and weakness, and there have been multiple independent reviews of the global response to COVID-19, with more than 300 recommendations to address the challenges or the weaknesses.

In response to those recommendations, WHO and our Member States have taken many steps to strengthen global health security: the Pandemic Fund; the WHO Hub for Pandemic and Epidemic Intelligence; the mRNA Technology Transfer Hub; the Global Training Hub for Biomanufacturing; the Global Health Emergency Corps; the interim Medical Countermeasures Network, and more. So, all of this has been established based on the lessons learned.

And as I mentioned earlier, Member States have committed to concluding negotiations on the Pandemic Agreement in time for this year's World Health Assembly.

## **Finally, the Executive Order says WHO has an “inability to demonstrate independence from the inappropriate political influence” of our Member States.**

As a UN agency, WHO is impartial and exists to serve all countries and all people. Our Member States ask us for many things, and we always try to help as much as we can.

But when what they ask is not supported by scientific evidence, or is contrary to our mission to support global health, we say no, politely. And you have seen me doing that many times.

As Member States know, that is what we have done on several occasions to countries of all income levels, in all regions...

.....  
.....

## **U.S. Actions – Global Health**

### **The Lancet**

Feb 08, 2025 Volume 405 Number 10477 p439-516

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

### **American chaos: standing up for health and medicine**

The Lancet

Withdrawal from WHO and the Paris Agreements. USAID shuttered and aid halted, ceasing health programmes globally. A freeze on US\$3 trillion worth of federal grants and loans, jeopardising the functioning of Medicaid. A sweeping pause on key activities across the National Institutes of Health (the world's largest biomedical research institution). Stop work orders at the Centers for Disease Control and Prevention (CDC). Denial of gender diversity. The Mexico City policy reinstated.

Communications blackouts, which saw the *Morbidity and Mortality Weekly Report* not published for the first time in 60 years. Donald Trump's actions domestically and globally are not a measured reappraisal of US priorities. They are a sweeping and damaging attack on the health of the American people and those dependent on US foreign assistance.

They are also an attack on the health and medical research community. Researchers' ability to work has been severely limited or stopped altogether. Free speech is restricted. Use of certain terms is banned on US Government websites (and in manuscripts submitted to scientific journals), including “gender”, “transgender”, “LGBT”, and “non-binary”, and a directive has paused the submission of new work for publication for all CDC employees and contractors. At *The Lancet*, the impact has already been felt. Reviewers are declining and authors are self-censoring. Health institutions may be hesitant to criticise the new administration publicly, but this timidity is a mistake. Trump's actions must be called out for the damage they are doing.

The 90-day freeze of US aid, including funds for the President's Emergency Plan for AIDS Relief—even with a waiver for “life-saving humanitarian programs”—has left services in limbo, particularly for HIV prevention and key populations. These are not abstract concerns. Swathes of health workers have been fired, clinics have closed, and patients have been affected, as World Reports in this issue show. Elon Musk has called USAID “evil” and a “criminal organisation”, peddling falsehoods in an attempt to justify gutting, if not abolishing, the agency. These decisions are deeply wrong, with far-reaching impacts that set back decades of gains in disease control and health equity. Trump's actions are a particular attack on women's health, notably sexual and reproductive health and rights. The gradual progress that has been made on climate and health is now likely to stall or even reverse. More people will get ill and more people will die.

This moment is a test. How should our community react? The immediate result has been confusion, disruption, and disorientation, but the response cannot be dictated by fear or resignation. There is a

need for focus, strategy, and—indeed—hope. Not all executive orders will survive legal challenges. Some orders have been tempered or adjusted thanks to civil society, journalists, government whistleblowers, and some members of Congress who have been vocal about the immediate harms. The health, medical, and scientific communities have a vital role in advocating for their patients, defending programmes, and lobbying for policies and institutions that are good for health and wellbeing. Bipartisan support for global health in the USA has given way to deep polarisation, and the global health community must contend with the fact that the USA is an unreliable partner. As Ilona Kickbusch notes in a Comment in this issue, other member states need to finance and build an organisation that is fit for the challenges ahead.

The health community has overcome huge obstacles many times before to make enormous contributions to humanity's wellbeing. Those experiences have crystalised a vision about what health is, and what it can be. That everyone has a right to health. That the health of Americans is contingent on the health of everyone, everywhere—and vice versa. That cooperation and constructive partnerships are vital, and that science has the ability not only to advance our understanding of the world but also to bring people together. That health is a social good, beneficial for societies, a driver of economies, and a path to development. That medicine can help people at their lowest, alleviate suffering, and improve lives. That equity—treating according to need—is fundamental to what medicine is. And that to care is an act not of weakness, but of strength.

The past 3 weeks have generated much anger, fear, and sorrow—but it is no time for panic. The medical and scientific communities must come together and stand up for this vision.

**In that spirit, *The Lancet* will be a focal point of accountability over the next 4 years, monitoring and reviewing the actions of the US Government and the consequences of its decisions for health.**

.....  
.....

## **Ebola**

### **[Groundbreaking Ebola vaccination trial launches today in Uganda](#)**

WHO 3 February 2025

In a global first, Uganda's Ministry of Health, the World Health Organization (WHO) and other partners today launched **a first-ever clinical efficacy trial for a vaccine from Ebola from the Sudan species of the virus, and at an unprecedented speed for a randomized vaccine trial in an emergency.** This is the first trial to assess the clinical efficacy of a vaccine against Ebola Sudan virus disease. IAVI, the provider of the vaccine, conducted trials for safety and immunogenicity. It is also the first clinical trial of the vaccine during an outbreak.

**The principal investigators from Makerere University and the Uganda Virus Research Institute (UVRI), with support from WHO and other partners,** have worked tirelessly to get the trial ready in 4 days since the outbreak was confirmed on 30 January. It is the first trial to assess the clinical efficacy of a vaccine against Ebola disease due to Sudan virus. The speed was achieved through advanced research preparedness, while ensuring full compliance with national and international regulatory and ethical requirements.

**The candidate vaccine was donated by IAVI,** with financial support from WHO, the Coalition for Epidemic Preparedness Innovations (CEPI), Canada's International Development Research Centre (IDRC), and the European Commission's Health Emergency Preparedness and Response Authority (HERA) and support from the Africa Centres for Disease Control and Prevention (Africa CDC).

"This is a critical achievement towards better pandemic preparedness, and saving lives when outbreaks occur," said Dr Tedros Adhanom Ghebreyesus, WHO's Director-General. "This is possible because of the dedication of Uganda's health workers, the involvement of communities, the Ministry of Health of Uganda, Makerere University and UVRI, and research efforts led by WHO involving hundreds of scientists through our research and development Filoviruses network. **We thank our partners for their dedication and cooperation, from IAVI for donating the vaccine, to CEPI, EU HERA and Canada's IDRC for funding, and Africa CDC for further support.** This massive achievement would simply not be possible without them."...

**The randomized vaccine trial to assess the recombinant vesicular stomatitis virus (rVSV) candidate vaccine** was launched at a ceremony in Kampala today by the Minister of Health of Uganda. WHO is co-sponsoring the trial. WHO was represented by Dr Mike Ryan, Executive Director of WHO's Health Emergencies Programme and Deputy Director-General, and the WHO representative to Uganda Dr Kasonde Mwinga, along with other colleagues.

**Three vaccination rings were defined today. The first ring involves about 40 contacts and contacts of contacts of the first reported and confirmed case, a health worker who has died.**

Although several promising candidate medical countermeasures are progressing through clinical development, **as of now, there is no licensed vaccine available to effectively combat a potential future outbreak of Ebola disease from the Sudan species of the virus.** Licensed vaccines exist only for the disease caused by Ebola virus, formerly known as Zaïre ebolavirus. Likewise for treatments, approved treatments are only available for Ebola virus.

The vaccine for the trial was recommended by the independent WHO candidate vaccine prioritization working group. If the candidate vaccine is effective, it can contribute to controlling this outbreak and generate data for vaccine licensure.

In 2022, the research teams were trained in good clinical practice (GCP) and standard operating procedures for such trials. They completed refresher training in recent days. WHO colleagues experienced in trials and in ring vaccination arrived in Uganda over the weekend to support the trial implementation and GCP compliance.

**The vaccine doses were pre-positioned in the country. WHO worked with the principal investigators and national authorities and the vaccine developer to review cold chain documentation and ensure the doses were stored correctly over the previous years. As part of the signed agreement with the Ministry of Health, WHO has a signed agreement with IAVI for additional doses of the candidate vaccine to be made available shortly.**

.....  
.....

### [Global vaccine market report 2024](#)

WHO 3 February 2025

#### *Overview*

...Understanding vaccine markets is a key input to increasing access to vaccines and a critical component to improving immunization coverage. **The 2024 GVMR provides a snapshot of vaccine markets globally in 2023, covering 88 vaccine products sold in 207 countries and procurement channels by 116 manufacturers.** The report analyses market trends between different country income groups and regions and over time using historical data, to support an

improved understanding of individual vaccine markets as well as cross-cutting issues. The insights from this report provide valuable market intelligence to governments, industry, global public health agencies, and other key decision-makers. It helps identify challenges and opportunities to accelerate equitable access to vaccines worldwide, aligning with the Call to Action issued in the 2022 GVMR, which remains highly relevant today.

This year's GVMR assesses vaccine procurement data from the year 2023. Short-term evolution of the market is analysed through comparisons to data from 2022. Trends compared to 2019 are also analysed to enhance understanding of pre-pandemic and post-pandemic market dynamics

## **Key takeaways**

### **1 Volume and financial value**

**Aggregate global vaccine market volumes in 2023 stabilized at a level similar to pre-COVID, due to reduced procurement of COVID-19 vaccines.** Total global market volumes were approximately 7 billion doses in 2023, almost half of the 2022 volumes, a notable decrease due to reduced purchases of COVID-19 vaccines. In total, 50% of volumes were accounted for by three vaccines: oral polio (OPV), COVID-19 and seasonal influenza vaccines. Big volume increases were observed in HPV and smallpox/mpox vaccine due to programme expansion and increased outbreak response respectively. The compound average growth rate (CAGR) of the global vaccine market in volumes was 3% over the past five years (2019-2023) and was mainly driven by demand for COVID-19 vaccines.

**The global vaccine market's financial value experienced a larger growth of 15% CAGR over the past five years.** The relatively high increase in financial value is driven by increased procurement of higher priced adult vaccines in high-income countries – e. g. COVID-19, pneumococcal conjugate vaccine (PCV) and shingles – and the purchase of novel respiratory syncytial virus (RSV) vaccines (for adults and maternal use) and monoclonal antibodies (mAb) for protection of infants. Moreover, significant financial value growth in China, driven primarily by private market procurement of PCV and HPV vaccines, has contributed to the overall growth. COVID-19 remained the vaccine accountable for the highest global financial value, at US\$ 20 billion and 27% of total market value in 2023.

### **2 Manufacturing and supply**

**The global vaccine market remains highly concentrated between a limited number of manufacturers, with the largest 10 manufacturers accounting for 73% of vaccine dose volumes and capturing 85% of global financial value.** More than 90 manufacturers account for the remaining global volumes. Manufacturers affiliated with the Developing Country Vaccine Manufacturers Network (DCVMN) sold more than 50% of vaccine doses procured globally, representing 11% of the global financial value, while manufacturers affiliated with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) accounted for approximately 85% of financial value, representing 34% of total volume.

**Dependence on a few large manufacturers** – Pfizer, the Serum Institute of India (SII), GSK, Sanofi, Merck/MSD, Bharat Biotech (BBIL) – with broad portfolios and use of multiple technology types is evident, with Pfizer and SII being outliers from financial value and volume perspectives.

### **3 National stock-outs**

**National stock-outs have remained a problem for many countries**, with 68 countries reporting at least one stockout at the national level in 2023. The number of national stock-outs reported has ranged between 67-88 in the past 5 years, mostly in the same countries.

### **4 Vaccine specific supply dynamics and supply security**

**Countries in the WHO African and Eastern Mediterranean regions continued to procure vaccines manufactured almost entirely outside their respective regions.** Efforts to expand



local production in these regions, with support from the international community are underway but will take time to materialize.

**The WHO South-East Asia region and the WHO Western Pacific region look highly self-sufficient, with the former self-supplying 87% of vaccines procured**, and the latter self-supplying 66% of vaccine procured. Nevertheless, this picture can be mostly attributed to India and China, with the former providing 84% of the doses procured in its region and self-supplying 99% of its own procurements, and the latter providing 54% of the WHO Western Pacific region and self-supplying 90% of its own procurements.

## **5 Procurement and pricing**

**Self-procuring middle-income countries (MICs) represented approximately 40% of market volumes, followed by pooled procurement initiatives (UNICEF and PAHO), which represented 36% of globally procured volumes in 2023** with self-procuring high-income countries (HICs) accounting for the remaining 24% of the volumes. From a financial value perspective, HICs continue to dominate with 72% of the financial value, up from 65% in 2022, while MICs account for 24% and pooled procurement accounts for the remaining 4% of the financial value.

Globally, vaccine prices have remained relatively stable in the last years. Vaccine prices within individual markets tend to be tiered across countries based on their income group, similar to previous years. Likewise, prices paid by self-procuring countries exhibited greater variability than prices paid by countries who used pooled procurement mechanisms, underlining the importance of UNICEF Supply Division (SD) for Gavi supported countries and PAHO Revolving Fund (RF) for access to vaccines for self-financing countries.

## **6 Vaccine regulation**

**In 2023, no additional national regulatory authority has achieved a maturity level sufficient to regulate vaccine production, leaving the global total at 34 authorities with maturity level (ML) 3 or higher for vaccine manufacturing.** To support regional diversification of manufacturing, the growth of national regulatory authorities of a sufficient ML to regulate vaccine production will be a critical factor. National authorities in countries where vaccine manufacturing is a priority are working towards higher ML, supported by WHO and partners.

.....  
.....

## **The Elders**

### **Pandemic prevention, preparedness and response: Proposals for action**

30 January 2025 :: 21 pages

A policy paper on pandemic preparedness and response, addressing six key themes for global reform. Founded by Nelson Mandela in 2007, The Elders are a group of independent global leaders working together for peace, justice, human rights and a sustainable planet.

### ***Executive Summary [Excerpts]***

The science is clear. The next pandemic threat is a matter of when, not if. There is a significant chance that a future pandemic could be some combination of more infectious, more likely to mutate and more fatal than COVID-19.



**As we mark the 5th anniversary of COVID-19's declaration as a public health emergency, it is evident that lessons have not been learnt and most recommendations from independent expert panels have not been implemented.**

This is a collective problem. We learned from COVID-19 that none of us are safe unless all of us are safe. Yet, humanity is struggling to put aside individual and national interests and act in our common interest. **Some people and governments are actively turning against actions that would significantly reduce risks. How can we break through this impasse?**

**This paper examines six critical themes requiring action** on the global pandemic reform agenda and concludes with targeted recommendations for each:

1. International attention and global leadership
2. A whole of society approach to pandemics
3. Equity, human rights and global solidarity
4. Sustainable financing
5. Disinformation and politicisation
6. The threats and opportunities of new technologies

### ***Our proposals for action [headlines summary]***

#### **1. International attention and global leadership**

- Championing of pandemic PPR by one or more world leaders.
- Establish a global leadership body on pandemic PPR.
- Increase engagement by the UN leadership on pandemics.
- Strengthen political support for the WHO.
- Develop pandemic monitoring and accountability mechanisms.

#### **2. A whole-of-society approach to pandemics**

- Integrate pandemics into other policies.
- Develop a multisectoral global action plan for pandemics.
- Identify solutions that tackle both pandemic and climate risks.
- Appoint national pandemic authorities

#### **3. Equity, human rights and global solidarity**

- Operationalise equity in the Pandemic Accord.
- Support regional and national self-reliance for the development of medical countermeasures.
- Develop fair and unified global pandemic surveillance platforms.
- Pursue a meaningful dialogue on the impact of the TRIPS Agreement on availability of pandemic countermeasures.
- Facilitate inclusive policy-making to drive equity.
- Embed the vital role of Community Health Workers in the pandemic architecture.
- Invest in gender mainstreaming across the health emergency cycle.

#### **4. Sustainable financing**

- Increase and coordinate official development assistance financing for pandemics
- Coordinate the financing architecture for pandemics.
- Reform IFIs to generate more pandemic finance.
- Secure funding flows for pandemics and other global public goods through global tax reform and debt restructuring.

#### **5. Disinformation and politicisation**

- Place scientific evidence at the centre of policy development
- Include global health security in forums for global debates on tackling misinformation

and disinformation.

- Mainstream disinformation management into pandemic PPR.

## **6. The threats and opportunities of new technologies**

- Mainstream biosecurity into the broader global health security dialogues on pandemic PPR.
- Implement the commitments on biological weapons in the UN Pact for the Future.
- Improve biosecurity regulation to ensure that it responds to fast advances in biomedical research and development, including around laboratory security and AI.

## **Conclusion**

Since the declaration of COVID-19 as a Public Health Emergency of International Concern on 30 January 2020, not enough has been done to break the cycle of panic and neglect that characterises the world's approach to pandemics.

This is not for want of evidence or recommendations. It is **a failure of political will caused by short-term thinking.**

Leaders are confronted with a choice: address pandemic threats before it is too late, or leave ourselves vulnerable to a future pandemic that could be worse than COVID-19.

The scientific and economic analysis is clear: the benefits of investing now to strengthen global pandemic capabilities by far outweigh the costs. Those benefits and costs need to be equitably allocated around the world based on a spirit of solidarity that was tragically missing during COVID-19.

COVID-19 underscored how interconnected and interdependent we are as a human species. It shone an unforgiving light on the failures of nationalist policies and individualistic behaviour at all levels of society.

But it also prompted countless acts of solidarity and sacrifice, from which leaders, policymakers, and civil society should all draw inspiration in the years ahead. Equitable pandemic prevention, preparedness and response is a moral and political imperative. It can only be delivered by leaders who think holistically and take a long view of what is best for their people and the world.

We owe it to all those who died from COVID-19 and their families and communities to ensure that future policies are fair, funded, and fit for purpose. But most of all, we owe it to those who are at risk of dying or having their lives ruined by an even more lethal pandemic – which could be all of us.

A healthy, secure and equitable future is within reach if leaders act now with principle and determination.

.....  
.....

## **mPox – PHEIC**

*No new digest content identified.*

.....  
.....

## Polio – PHEIC

### Polio this week – 05 February 2025

#### **Headlines**

- Poliovirus detections in Europe – urgent action needed to keep Europe polio-free. Click [here](#) for an editorial by Pamela Rendi-Wagner, Director of the European Centre for Disease Prevention and Control (ECDC) and Hans Kluge, WHO Regional Director for Europe, on the recent detections of poliovirus which highlight the ongoing risk of polio resurgence anywhere.

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Pakistan: 39 WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample

.....  
.....

## Public Consultations/Call for Inputs/Call for Papers

### E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 12/30/2024 **Comment period ends 02/28/2025**  
*SUMMARY:*

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E6(R3) Good Clinical Practice: Annex 2." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second annex to "E6(R3) Good Clinical Practice" published June of 2023. This annex provides additional considerations for the application of good clinical practices to a variety of trial designs and data sources. Specifically, this draft guidance discusses trials with decentralized and pragmatic elements and real-world data sources. This draft guidance highlights the importance of quality by design and focusing efforts and resources on critical aspects of the trials that might impact the safety of participants and the reliability of results. The draft guidance is intended to encourage innovation in trial design and provides flexible, modern, and clear good clinical practices for conducting trials, while avoiding unnecessary complexities.

.....  
.....

#### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)  
:: [\*WHO\*](#)  
:: [\*Organization Announcements\*](#)  
:: [\*Journal Watch\*](#)  
:: [\*Pre-Print Servers\*](#)

.....  
.....

## **WHO & Regional Offices** [to 08 Feb 2025]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

7 February 2025 *News release*

**Dire health and humanitarian crisis in eastern Democratic Republic of the Congo prompts escalation of efforts by WHO, partners**

6 February 2025 *Joint News Release*

**[Strengthening alliances and building movements to end female genital mutilation](#)**

**[Groundbreaking Ebola vaccination trial launches today in Uganda](#)**

3 February 2025

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

:: 04 February 2025

**[Urgent action needed to reinforce breast cancer control measures in Africa: WHO report](#)**

**WHO Region of the Americas PAHO**

:: 5 Feb 2025

**[Countries of the Americas to have access to the HPV9 vaccine through the PAHO Revolving Fund from mid-2025](#)**

Washington, D.C., 5 February 2025 – The Pan American Health Organization (PAHO) has announced that the 9-valent HPV vaccine will be available to countries of the Americas via its Revolving Fund for Access to Vaccines starting July 2025. This will facilitate more affordable, efficient access to the vaccine, which provides protection against 9...

:: 4 Feb 2025

**[Epidemiological Alert: Increase in Yellow Fever Cases in Latin America](#)**

Washington, DC, February 4, 2025 (PAHO) - The Pan American Health Organization (PAHO) has issued an epidemiological alert regarding yellow fever in the Americas due to the recent increase in confirmed human cases in several countries in the region and a change in the geographic distribution of the disease. This increase has been observed over the...

:: 3 Feb 2025

**[PAHO calls on Latin American and Caribbean countries to improve access to essential cancer medicines and supplies](#)**

Washington, DC, February 3, 2025 (PAHO)– On the eve of World Cancer Day (February 4), the Pan American Health Organization (PAHO) is urging governments in Latin America and the Caribbean to prioritize access to essential cancer medicines, supplies, and equipment. Cancer remains one of the leading causes of death in the Americas region, claiming...

**WHO South-East Asia Region SEARO**

*No new digest content identified.*

**WHO European Region EURO**

*No new digest content identified.*

**WHO Eastern Mediterranean Region EMRO**

**[:: Layla's journey to vaccinate her son during The Big Catch-up in Somalia](#)**

6 February 2025

**WHO Western Pacific Region**

:: 30 January 2025

**[Lao PDR Ministry of Health pilots text message vaccine reminders for childhood immunization...](#)**

.....

### **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

### **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 100, No. 06, pp. 41–44 7 February 2025**

PDF: <https://iris.who.int/bitstream/handle/10665/380408/WER10006-eng-fre.pdf>

:: Notes from the field: Detection of vaccine-derived poliovirus type 2 (VDPV2) in wastewater in 5 European countries, September–December 2024

.....

### **New WHO Publications**

<https://www.who.int/publications>

*Selected*

7 February 2025

**[WHO pharmaceuticals newsletter - No. 5, 2024](#)**

*Overview*

The WHO pharmaceuticals newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.

In addition, this edition includes the meeting report of the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP), 13-14 May 2024.

6 February 2025

**[Global research agenda for antimicrobial resistance in human health](#)**

*Overview*

The World Health Organization's global research agenda for antimicrobial resistance in human health is the first of its kind, developed to promote the generation of evidence with the greatest potential to mitigate AMR in the human health sector by 2030. The agenda outlines 33 research priorities addressing bacterial and fungal infections and seven priorities specifically addressing multidrug-resistant tuberculosis, identified through a rigorous prioritization exercise based on a literature review and expert opinion.

Designed to guide policymakers, researchers, funders and other stakeholders, the agenda aims to catalyse research and investment aligned with the identified priorities. It emphasizes the need to translate research priorities into actionable, implementable studies to ultimately inform AMR policies and interventions—especially in resource-limited settings.

4 February 2025

**[Evaluation of WHO 13th General Programme of Work](#)**

4 February 2025

[Infection prevention and control and water, sanitation and hygiene measures for home care and isolation for mpox in resource-limited settings: interim operational guide](#)

3 February 2025

[Global vaccine market report 2024](#)

.....  
.....

## **USA – HHS, FDA, CDC**

### **HHS**

*News*

[HHS' Civil Rights Office Acts Swiftly to Combat Anti-Semitism](#)

February 3, 2025 News Release

### **FDA**

*Press Announcements*

*No new digest content identified.*

### **FDA VRBPAC**

*Advisory Committee Calendar*

*No new VRBPAC calendar dates identified.*

### **CDC/ACIP [U.S.] [to 08 Feb 2025]**

<http://www.cdc.gov/media/index.html>

*Latest News*

*Last news release 10 Jan 2025.*

*Webpage advisory: "CDC's website is being modified to comply with President Trump's Executive Orders."*

### **ACIP Meetings**

*Next ACIP Meeting*

February 26-27, 2025

[Agenda for February 26-28](#)

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2024.html>

*The January 16th MMWR [below] which we carried in our last edition no longer appears on the MMWR webpage. We note the two ACIP recommended immunization schedules that comprise this edition. The PDF link below is still active.*

### **MMWR Weekly, January 16, 2025 / No. 2**

[PDF of this issue](#)

- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025](#)
- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025](#)

.....  
.....

## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

*No new digest content identified.*

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*Assessment*

#### **Rapid risk assessment - Carbapenem-resistant Enterobacterales – third update**

3 Feb 2025

Carbapenem resistance in Enterobacterales, such as *Klebsiella pneumoniae* and *Escherichia coli*, poses a significant threat to patients and healthcare systems in European Union/European Economic Area (EU/EEA) countries.

.....

.....

### Africa CDC [to 08 Feb 2025]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

*Press Releases*

#### **New Dawn for Health Security and Sovereignty in Africa as Stakeholders Convene at Manufacturing Forum**

Cairo, Arab Republic of Egypt February 5, 2025 – The 2nd Vaccine and Other Health Products Manufacturing Forum, organized by Africa CDC, Gavi, the Vaccine Alliance, the Regionalized Vaccine Manufacturing Collaborative (RVMC), and the Unified Procurement Authority of Egypt (UPA), has concluded in Cairo, Egypt. The three-day forum convened African Union (AU) Ministers of Health, Regional Economic Communities (RECs), Development Finance Institutions (DFIs), African vaccine manufacturers, policymakers, regulatory authorities, and international partners to discuss strategies to accelerate the development of a sustainable vaccine and health products manufacturing ecosystem in Africa.

The stakeholders reviewed progress, opportunities, and strategies to remove barriers that have held back regional manufacturing in the past, such as reforms to the region's regulatory environment, continental demand and access to finance...

*Press Releases*

#### **Landmark Agreement Among Africa's Leading National Medicines Regulatory Authorities to Foster Collaboration**

Cairo, Egypt, 4 February 2025: The Africa Centres for Disease Control and Prevention (Africa CDC) and African Union Development Agency – New Partnership for Africa's Development (AUDA-NEPAD) are proud to announce the signing of a Memorandum of Understanding (MoU) among Africa's WHO Maturity Level 3 National Regulatory Authorities (NRAs). These agencies have established robust systems to ensure the safety, efficacy and quality of medical products in line with international regulatory standards.

The agreement marks a significant milestone in strengthening regulatory systems across the continent by fostering collaboration and reliance on regulatory decisions among signatory agencies while also creating an enabling environment for the local production of medical products. It aims to



create a framework that streamlines regulatory decisions to speed up the approval of medicines, vaccines and medical devices, while promoting collaboration on vaccine lot releases.

The MoU was signed by Ghana's Food and Drugs Authority (FDA), the National Agency for Food and Drug Administration and Control (NAFDAC) of Nigeria, Rwanda Food and Drugs Authority (FDA), the Senegalese Pharmaceutical Regulatory Agency (ARP), South African Health Products Regulatory Authority (SAHPRA), Tanzania Medicines & Medical Devices Authority (TMDA), and Medicines Control Authority of Zimbabwe (MCAZ)...

.....

### **China CDC+**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China** [to 08 Feb 2025]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC** [to 08 Feb 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

### **China CDC**

#### **CCDC Weekly Reports: Current Volume (7)**

**2025-02-07 / No. 6**

[PDF of this issue](#)

- [Review: Advances in HPV-Associated Cervical Cancer Dynamic Modelling for Prevention and Control Evaluation](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, December 2024\\*](#)

.....

.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

### ***Organization Announcements***

### **Paul G. Allen Frontiers Group** [to 08 Feb 2025]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 08 Feb 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*Press release Feb 05, 2025*

**Tanzania's Progress in Maternal and Child Health Earns Global Recognition from Gates Foundation**

DAR ES SALAAM (5 February 2025) – President Samia Suluhu Hassan was presented the Global Goalkeeper Award by the Gates Foundation in recognition of Tanzania's remarkable achievements in maternal, newborn, child nutrition and health (MNCNH)...

**Bill & Melinda Gates Medical Research Institute** [to 08 Feb 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 08 Feb 2025]

<https://carb-x.org/>

*News*

02.06.2025 |

**CARB-X funds AstraDx to develop rapid diagnostic to detect neonatal sepsis**

CARB-X will award AstraDx US\$3M to demonstrate feasibility ahead of development for a robust, low-cost instrument to detect neonatal sepsis. AstraDx's technology aims to perform pathogen detection, pathogen identification, and phenotypic antimicrobial susceptibility testing (AST) directly from whole blood and produce results within 4 hours.

**Chan Zuckerberg Initiative** [to 08 Feb 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

Feb 6, 2025

**CZI Launches Billion Cells Project With 10x Genomics and Ultima Genomics To Advance AI in Biology**

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 08 Feb 2025]

<http://cepi.net/>

*CEPI News, Blog*

*News*

**Pushing mRNA vaccine development timelines to new speeds**

New technology could streamline production of mRNA and improve global access

5 Feb 2025

*News*

**Groundbreaking study in Rwanda to unlock new insights into Marburg virus immunity**

4 Feb 2025

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 08 Feb 2025]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 08 Feb 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [to 08 Feb 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*Press releases* 4 Feb 2025

**Hyundai Bio (HDB) and DNDi sign MOU for joint development of Xafty-based dengue treatment**

**Duke Global Health Innovation Center** [to 08 Feb 2025]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 08 Feb 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*No new digest content identified.*

**Emory Vaccine Center** [to 08 Feb 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 08 Feb 2025]

<http://www.euvaccine.eu/>

*Latest News, Events*

**VACCELERATE concludes: achievements from the first Europe's Corona Vaccine Trial**

07 Feb 2025

**Fondation Merieux** [to 08 Feb 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 08 Feb 2025]

<https://www.gavi.org/>

*Press Releases*

6 February 2025

**2024 WHO-CDC measles report & the State of measles vaccination in lower-income countries**

6 February 2025

**One year anniversary of malaria vaccine rollout underscores remarkable progress, offers new data on potential impact**

*Snap Analysis*

Geneva, 22 January 2025 – One year since the launch of routine malaria vaccinations in Africa, over 9.8 million doses of malaria vaccines (in total 12 million since 2023) have been delivered to 17 endemic countries through the Gavi malaria vaccination programme.

Surpassing the initial target of 15 countries, the pace of rollout is an indication of the high demand for this new tool as well as years of preparation by countries and partners. In total, an estimated 5 million children in these 17 countries that collectively represent more than 70% of the world's malaria burden have been protected.

And one year into the programme, promising early results are emerging...

5 February 2025

**Stakeholders discuss progress, next steps for Africa's health security at Manufacturing Forum**

- The 2nd Vaccine and Other Health Products Manufacturing Forum, organised by Africa CDC, Gavi, the Vaccine Alliance, the Regionalized Vaccine Manufacturing Collaborative (RVMC) and the Unified Procurement Authority of Egypt, opened in Cairo, the Arab Republic of Egypt.
- The Forum convenes African Union Ministers of Health, National Regulatory Authorities (NRAs), Regional Economic Communities (RECs), African Union organs, African manufacturers, manufacturers' associations, AVMA investors, global and international partners, philanthropies and CSOs to discuss challenges and potential solutions to unlock the potential of local manufacturing, and ensure sustainable coordination efforts to manufacture vaccines and other health priority products in Africa.
- "At Gavi, we are committed to playing our role in this multisectoral effort to invest and build capacity across the value chain. Building a sustainable vaccine and health products manufacturing ecosystem would not only help meet the continent's health needs, it would also deliver economic growth and enable African nations to take charge of their health future," said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance.

**GE2P2 Global Foundation** [to 08 Feb 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 14 Jan 2025](#)

**GHIT Fund** [to 08 Feb 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 08 Feb 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 08 Feb 2025]

<https://www.glopid-r.org/news/>

*News*

[Outbreak Page on Marburg Virus Disease in Tanzania by Pandemic PACT](#)

February 3, 2025

**Hilleman Laboratories** [to 08 Feb 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 08 Feb 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 08 Feb 2025]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 08 Feb 2025]

<https://www.iavi.org/>

*Press Releases*

[First participants vaccinated with IAVI's Ebola Sudan vaccine candidate in Uganda amid Ebola outbreak](#)

February 3, 2025

The vaccine candidate is being evaluated in a ring vaccination trial as part of a comprehensive public health response.

**INSERM** [to 08 Feb 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

### **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

### **ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 08 Feb 2025]**

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

### **ICRC [to 08 Feb 2025]**

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

#### **"People have the power to change the course of history": ICRC President at the European Conference, Harvard University**

Statement

03-02-2025

... We are living in a time of unforeseen convergence of events that will shape our world's future, and Europe's role in it.

As at every critical juncture in history – we witness the foundations of both law and diplomacy coming under immense strain.

Because the world is deeply divided. Because conflicts are increasing in number and escalating in intensity. International humanitarian law – the rules that seek to protect humanity in war – is too often disregarded, violated, and even ignored all together.

This is undeniably the reality we face today. But I want you to acknowledge – especially those of you who hold or intend to take the reins of global leadership positions – that there is another truth to this: at the very end, multilateralism prevails...

### **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

#### **After pandemic setback and natural disasters, Malawi school teachers help dial up HPV vaccine uptake**

03 Feb 2025

The government's strategy of training up teachers to explain the science to confused or worried parents is working, learns Ashley Simango.

### **IFRC [to 08 Feb 2025]**

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

#### **Türkiye and Syria earthquakes two years on: A long road to recovery**

05/02/2025 | *Press release*

### **IPPS - International Pandemic Preparedness Secretariat**

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

### **Institut Pasteur** [to 08 Feb 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

### **ISC / International Science Council** [to 08 Feb 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

**[Science, ethics, and power: The need for a global commons approach to emerging technologies](#)**

February 5, 2025

As the United Nations launches the Year of Quantum Science and Technology, the promise of breakthroughs in quantum computing and space exploration comes with pressing ethical and geopolitical challenges. In September 2024, the World Commission on the Ethics of Scientific Knowledge and Technology (COMEST) convened to address these issues, emphasizing the need for a global commons approach.

### **International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**[19th International Congress of Immunology](#)**

Vienna, August 17-22, 2025.

### **IVAC** [to 08 Feb 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

### **IVI** [to 08 Feb 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

### **Johns Hopkins Center for Health Security** [to 08 Feb 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*



**MSF/Médecins Sans Frontières** [to 08 Feb 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Syria*

**MSF mobile clinics bring care to Syria's neglected region of east Ghouta**

Project Update 6 Feb 2025

*Gaza-Israel war*

**"Inflicting harm and denying care" in the West Bank**

Report 6 Feb 2025

*Conflict in Sudan*

**Mass influxes of wounded patients arrive at hospitals across Sudan as "war on people" continues**

Press Release 5 Feb 2025

*Tanzania*

**MSF team supports response to outbreak of Marburg virus in Tanzania**

Press Release 3 Feb 2025

*Conflict in Sudan*

**MSF renews call for immediate action to prevent death and starvation in Sudan**

Press Release 3 Feb 2025

**National Academy of Medicine** - USA [to 08 Feb 2025]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 08 Feb 2025]

<https://www.nationalacademies.org/newsroom>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 08 Feb 2025]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 08 Feb 2025]

<http://www.nih.gov/>

*News Releases*

*Last announcement: 17 January 2025*

**PATH** [to 08 Feb 2025]

<https://www.path.org/media-center/>

*Newsroom*

### **Dr. Gonzalo Domingo named leader of PATH's Diagnostics Program**

February 4, 2025 by PATH

... Dr. Domingo will lead our team of experts in diagnostic innovations, whose work has resulted in numerous diagnostic tools that have improved point of care evaluation and treatment in low-resource settings. The Diagnostics Program's experience encompasses research and development of point-of-care tests and rapid diagnostic tests, as well as conducting product evaluation and down selection to inform which products will be best; their work includes developing reference standards and core reagents to advance the diagnostics field. The team's breadth of expertise spans myriad infectious and other diseases and multiple platforms...

### **Sabin Vaccine Institute** [to 08 Feb 2025]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

### **UNAIDS** [to 08 Feb 2025]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Last update: 07 February 2025*

### **Impact of recent U.S. shifts on the global HIV response**

... On 1 February 2025, the U.S. Department of State's Bureau of Global Health Security and Diplomacy (GHSD), which oversees PEPFAR, issued a memo to PEPFAR Implementing Agencies and PEPFAR Country Coordinators on the implementation of the waiver, confirming that only the following activities should be continued / resumed during the 90-day pause:

1. Life-saving HIV care and treatment services, inclusive of HIV testing and counseling, prevention and treatment of opportunistic infections including TB, laboratory services, and procurement and supply chain for commodities/medicines.
2. Prevention of mother-to-child transmission services, inclusive of commodities/test kits, medicines and PrEP for pregnant and breastfeeding women.
3. Reasonable implementing agency and implementing partner administrative costs strictly necessary to deliver and provide oversight of this assistance.
4. PEPFAR implementing agencies were also instructed to pause U.S. foreign assistance for all other activities not covered by the waiver.

### **UNICEF** [to 08 Feb 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Remarks 04 February 2025*

### **UNICEF Executive Director Catherine Russell's remarks at the first regular session of the UNICEF Executive Board**

NEW YORK, 4 February 2025 – [Excerpt]

..."An example of this, which we will discuss in more detail, is the **Vaccine Independence Initiative**, or VII. As countries increasingly rely on domestic financing of supply purchases, the Initiative is an important tool in our work to provide access to essential supplies for children, beyond vaccines.

"VII acts as a revolving fund that supports countries using domestic resources for lifesaving supplies to bridge short-term funding gaps that could otherwise lead to delays in procurement and delivery. This enables interventions to move forward quickly, so that critical supplies can reach children on time.

"Between 2020 and 2024, VII support to countries increased exponentially – with a throughput of over \$1.7 billion in essential supplies for children, and more than 100 countries supported. This included nearly 1 billion doses of vaccines and 9 million cartons of RUTF that reached children faster than would have otherwise been possible.

"Beyond the VII, I am pleased to confirm that we continue our strong commitment and work to procure supplies and contracted services in support of countries for children across the world, in immunization, health, nutrition, education and other sectors. This enables governments and other partners to leverage UNICEF's procurement scale and expertise.

"Preliminary figures for 2024 show that we procured a total of \$5.4 billion of supplies and contracted services. More than \$2.3 billion of this procurement was performed on behalf of governments and development partners, using their own resources...

**Unitaid** [to 08 Feb 2025]

<https://unitaid.org/>

*Featured News*

*Statements*

**Unitaid remains committed to equitable access to critical health innovations**

06 February 2025

Unitaid is deeply concerned about the potential impact of the unexpected suspension of foreign aid on the lives and livelihoods of hundreds of millions of people worldwide.

The sudden changes to global health have greatly limited access to critical health services for all populations at risk of HIV, tuberculosis, malaria, and other major drivers of illness and death in low- and middle-income countries. Underserved populations including women and children, and marginalized or vulnerable groups will likely face the most serious consequences.

The recent actions are part of a foundational shift that poses challenges to the international aid system and to our collective capacity to address pressing global health issues.

While we are hopeful that the impact of these disruptions will be minimized following the United States' exemption to the aid freeze in support of lifesaving medicines and medical services, the full impact of these changes on countries, and our partners, implementers, and investments is not yet clear. We have launched an assessment to better understand the implications of these changes and determine how we can best respond in support.

Our commitment to equitable access to optimized health tools remains our top priority. We will continue to work closely with partners, countries and communities to navigate and respond to the abrupt developments in global health funding, access and markets, ensuring continued progress in addressing HIV, TB, malaria, and women's and children's health, despite the current challenges.

**Vaccine Equity Cooperative [nee Initiative]** [to 08 Feb 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 08 Feb 2025]

<https://www.vaccineacceptance.org/>

*No new digest content identified.*

**Vaccine Confidence Project** [to 08 Feb 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 08 Feb 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 08 Feb 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

**[The Human Genome Project: a new era of scientific progress](#)**

6 February 2025

The Human Genome Project was one of the most significant scientific endeavours in history, fundamentally transforming our understanding of human biology. Completed in 2003, it accelerated scientific progress and laid the groundwork for future innovations in health and medicine. Wellcome contributed £210 million to the effort.

**The Wistar Institute** [to 08 Feb 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

February 5, 2025

**[The Wistar Institute Scientists Discover New Weapon to Fight Treatment-Resistant Melanoma](#)**

PHILADELPHIA — (February 5, 2025) —The lab of The Wistar Institute’s Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

**World Bank** [to 08 Feb 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 08 Feb 2025]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**[World Medical Association \[WMA\]](#)** [to 08 Feb 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**[Physician Leaders Urge U.S. to Sustain Global Health Support Amid Foreign Aid Review](#)**

03.02.2025

The World Medical Association (WMA) is calling on the U.S. government to ensure the continuation of essential medical and humanitarian aid during the 90-day pause on foreign assistance mandated by the recent Executive Order on Reevaluating and Realigning United States Foreign Aid.

The presidential order, issued on January 20, 2025, halts new obligations and disbursements of development assistance funds while programs undergo review for alignment with U.S. foreign policy. Freezing essential humanitarian aid and critical healthcare programs could endanger vulnerable populations worldwide, WMA warns while acknowledging the administration's focus on reassessing aid efficiency and setting new priorities.

"We urge the U.S. government to preserve life-saving medical assistance. Healthcare transcends politics—pausing aid now could lead to devastating consequences for those most in need," said WMA President Dr. Ashok Philip.

The WMA also calls on other nations to step in and reinforce global health efforts to prevent disruptions in vital medical services. "At a time when infectious diseases, malnutrition, and humanitarian crises persist, international cooperation is essential," Dr. Philip added.

The WMA remains committed to advocating for uninterrupted healthcare delivery and urges all governments to prioritise healthcare as a fundamental global responsibility.

### **World Organisation for Animal Health [OIE]** [to 08 Feb 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....  
.....

### **ARM [Alliance for Regenerative Medicine]** [to 08 Feb 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

### **BIO** [to 08 Feb 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

### **DCVMN – Developing Country Vaccine Manufacturers Network** [to 08 Feb 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

### **ICBA – International Council of Biotechnology Associations** [to 08 Feb 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

### **IFPMA** [to 08 Feb 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*Statement 7 Feb 2025*

**156th WHO Executive Board (EB156): Constituency statement on climate change and health**

On 7 February 2025 at the EB156 in Geneva, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), and International Hospital Federation (IHF) delivered a statement on Agenda Item 22: Climate change and health.  
Read more

*Statement 7 Feb 2025*

**156th WHO Executive Board (EB156): Fight the Fakes Alliance statement on substandard and falsified products**

On 7 February 2025 at the EB156 in Geneva, the Fight the Fakes Alliance delivered a statement on substandard and falsified medical products. IFPMA is a member of Fight the Fakes Alliance.

*Statement 6 Feb 2025*

**156th WHO Executive Board (EB156): Constituency statement on health emergencies**

On 6 February at the EB156, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients' Organizations (IAPO), and International Generic and Biosimilar Medicines Association (IGBA) delivered a statement on Agenda Item 15: WHO's work in health emergencies.

*Statement 5 Feb 2025*

**156th WHO Executive Board (EB156): Individual statement on non-communicable diseases**

On 5 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).

**International Alliance of Patients' Organizations – IAPO** [to 08 Feb 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

**Joint Industry Statement for WHO's Executive Board Meeting 156 (February 2025)**

*The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients' Organizations (IAPO), and International Generic and Biosimilar Medicines*

We thank the World Health Organization for its continued work on health emergencies. The year of 2024 demonstrated that there is still a lot to do to improve health emergencies preparedness and response.

Outbreaks of Mpox, Marburg virus, and H5N1 have shown the need to strengthen healthcare systems, enhance surveillance mechanisms, improve regulatory procedures, remove trade barriers, and develop accurate forecasts to guide the scale up of production.

In strengthening preparedness and response for health emergencies, there needs to be a clear focus on how to achieve equitable access to vaccines, diagnostics, and treatments while also safeguarding innovation.

**While the World Health Organization must have a key role in future health emergencies preparedness and response, its resources are limited and should be focused on normative, policy, and technical guidance.** As The Independent Panel for Pandemic Preparedness & Response (IPPR) rightly said in its final report, "WHO is and should be the lead health organization in the international system, but it cannot do everything. It is imperative that the international preparedness and response system work together at the global, regional, and country levels as a well-defined and well-coordinated system in support of countries where different actors' comparative advantages are maximized."

**In order to achieve its target objective, it can only do so by engaging all key stakeholders and subject matter experts, which includes a strong engagement with the private sector. We therefore recommend that, in support of our joint objective of achieving a future effective health emergencies preparedness and response, WHO consistently and systemically ensure the inclusion of the private sector in its health emergency initiatives and dialogue.** We remain committed to working with the WHO and other global health stakeholders and to continuing to engage in the Intergovernmental Negotiating Body process to ensure that the world is better prepared for future health emergencies

**PhRMA** [to 08 Feb 2025]

<http://www.phrma.org/>

*Press Releases*

**[PhRMA Congratulates President Donald Trump on His Inauguration](#)**

January 20, 2025

...The pharmaceutical industry is the crown jewel of the American economy, giving American patients more treatment options than anywhere else in the world while supporting millions of high-paying, high-tech jobs around the country. Through innovation we've achieved significant breakthroughs, improved cancer survival rates, cured hepatitis C, **and eradicated devastating diseases like polio and smallpox.** New medicines are transforming our ability to prevent, treat, and cure deadly diseases more effectively, improving patient lives and reducing reliance on the most expensive parts of the health care system...

#### ***Editor's Note:***

We included the PhRMA press release above in last week's edition. When we visited the PhRMA site today to review and include any new announcements, this press release had been deleted. The link in the title of the press release above – active last week – now produces a 404 error. We did not identify any explanation for this deletion action on the PhRMA website..

.....  
.....

#### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

**AstraZeneca**

*Press Releases* - No new digest content identified.

**Bavarian Nordic**



Latest News - No new digest announcements identified

## **Bharat Biotech**

Press Releases - No new digest announcements identified

## **BioCubaFarma – Cuba**

Últimas Noticias

### **Reestructuración Organizacional y Movimiento de Cuadros**

Resumen: Como consecuencia del crecimiento y la proyección estratégica del Grupo de las Industrias Biotecnológicas y Farmacéuticas se realizó una reestructuración organizacional.

Jue, 06/02/2025 - 15:24

## **Biological E**

News - No new digest announcements identified

## **BioNTech**

Press Releases

### **BioNTech Completes Acquisition of Biotheus**

3 February 2025

- Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers
- With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies
- Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company's network

## **Boehringer**

Press Releases - No new digest announcements identified.

## **CanSinoBIO**

News - Website not responding at inquiry

## **CIGB**

Latest News - No new digest announcements identified.

## **Cinnagen**

Recent News - No new digest announcements identified.

## **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

## **Curevac**

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media - No new digest announcements identified.

## **EuBiologics, S Korea**

News - No new digest announcements identified.

**IMBCAMS, China**

Home - Website not responding at inquiry.

**JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

**Merck**

News releases - No new digest announcements identified

**Moderna**

Press Releases - No new digest announcements identified

**Nanogen**

News - No new digest announcements identified

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases - No new digest announcements identified.

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Sanofi Pasteur**

Press Releases - No new digest announcements identified.

**Serum Institute**

News & Announcements

**[Bilthoven Biologicals, a Cyrus Poonawalla Group company, opens Pandemic Preparedness Vaccine Facilities](#)**

The new state-of-the-art facilities have received approval from European Commission EU FAB and ensures vaccine accessibility for Europe in the event of a pandemic situation .

3 February 2025, Bilthoven, The Netherlands -

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

**Sinovac**

Press Releases - No new digest announcements identified.

**SK Biosciences**

Press Releases - No new digest announcements identified.

**Takeda**

Newsroom - No new digest announcements identified.

## **Valneva**

*Press Releases*

February 5, 2025

### **Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®**

...The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is manufactured at Valneva's leading vaccine production site in Livingston, Scotland....

## **Vector State Research Centre of Virology and Biotechnology**

*Home* - *[Website not responding [404 error]]*

## **WestVac Biopharma**

*Media* - *No new digest announcements identified.*

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

*Website* *[No News/Announcements page identified]*

.....  
.....

### ***Contents [click to move among sections]***

:: *Milestones, Perspectives*

:: *WHO*

:: *Organization Announcements*

:: *Journal Watch*

:: *Pre-Print Servers*

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

## **AMA Journal of Ethics**

Volume 27, Number 2: E67-166 Feb 2025

<https://journalofethics.ama-assn.org/issue/epidemiology-and-clinical-practice>

## ***Issue Theme: Pain Management in Non-Labor and Delivery OBGYN Procedures***

### **American Journal of Human Genetics**

Feb 06, 2025 Volume 112 Issue 2 p199-456

<https://www.cell.com/ajhg/current>

#### **This month in *The Journal***

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Many tools developed for genome-wide analyses perform best in cohorts of a single ancestry group. The genomes of admixed populations contain segments from different ancestry groups and vary from person to person. These features present challenges to investigators who would like to expand the depth, breadth, and diversity of their studies. One approach to control for population structure in admixed populations is local ancestry interference (LAI). By assigning ancestry groups to discrete genomic regions, LAI can boost the power of multiple genomic analyses.

#### *Review*

#### **Prenatal gene editing for neurodevelopmental diseases: Ethical considerations**

Rami M. Major, Eric T. Juengst

#### *Open Access*

Prenatal gene editing could someday safely and effectively treat numerous diseases. In this manuscript, we conduct a historical analysis of fetal therapy guidelines to suggest criteria that should be met for prenatal gene editing to reach the clinic. We discuss these considerations in the context of monogenic neurodevelopmental diseases.

#### *Perspective*

#### **Design and implementation of an action plan for justice, equity, diversity, and inclusion within the Clinical Genome Resource**

Alice B. Popejoy, et al.

The Clinical Genome Resource (ClinGen) describes the development and early implementation of a justice, equity, diversity, and inclusion (JEDI) action plan to enhance and integrate JEDI principles through concrete actions across the consortium and within the field of clinical genetics and genomics.

### **American Journal of Infection Control**

February 2025 Volume 53 Issue 2 p175-284

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

February 2025 Volume 68 Issue 2 p217-428

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

February 2025 115(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 1 (Jan 2025)  
<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.112.issue-1.xml>  
[Reviewed earlier]

### **Annals of Internal Medicine**

January 2025 Volume 178, Issue 1  
<https://www.acpjournals.org/toc/aim/current>  
[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 339 February 2025  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/339/suppl/C>  
*Review article Open access*

#### **Human-AI coevolution**

Dino Pedreschi, Luca Pappalardo, Emanuele Ferragina, Ricardo Baeza-Yates, ... Alessandro Vespignani  
Article 104244

#### *Abstract*

Human-AI coevolution, defined as a process in which humans and AI algorithms continuously influence each other, increasingly characterises our society, but is understudied in artificial intelligence and complexity science literature. Recommender systems and assistants play a prominent role in human-AI coevolution, as they permeate many facets of daily life and influence human choices through online platforms. The interaction between users and AI results in a potentially endless feedback loop, wherein users' choices generate data to train AI models, which, in turn, shape subsequent user preferences. This human-AI feedback loop has peculiar characteristics compared to traditional human-machine interaction and gives rise to complex and often "unintended" systemic outcomes. This paper introduces human-AI coevolution as the cornerstone for a new field of study at the intersection between AI and complexity science focused on the theoretical, empirical, and mathematical investigation of the human-AI feedback loop. In doing so, we: (i) outline the pros and cons of existing methodologies and highlight shortcomings and potential ways for capturing feedback loop mechanisms; (ii) propose a reflection at the intersection between complexity science, AI and society; (iii) provide real-world examples for different human-AI ecosystems; and (iv) illustrate challenges to the creation of such a field of study, conceptualising them at increasing levels of abstraction, i.e., scientific, legal and socio-political.

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 08 Feb 2025)  
[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 08 Feb 2025)

#### **Rapid Verbal Persuasion to increase influenza vaccine uptake: protocol for a randomized hybrid type 2 effectiveness -implementation trial**

*While influenza vaccines are the most effective measure for preventing influenza, uptake rates in China remain relatively low. Rapid Verbal Persuasion (RVP), with highly rapid fashion, has a strong evidence ba...*

Authors: Siyuan Liu, Lan Gao, Yingying Jin, Jiangyun Chen, Dadong Wu, Yiyuan Cai, Tao Wang, Sanhao Huang, Ciling Yan, Run Wang and Dong Roman Xu

Citation: BMC Health Services Research 2025 25:199  
Content type: Study Protocol Published on: 3 February 2025

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectedis/content>

(Accessed 08 Feb 2025)

#### **Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study**

Predictions regarding the on-going burden of SARS-CoV-2, and vaccine recommendations, require an *understanding of infection-associated immune protection. We assessed whether early COVID-19 provided protection ...*

Authors: Altynay Shigayeva, Christopher Kandel, Lubna Farooqi, Zoe Zhong, Anne-Claude Gingras, Brenda L. Coleman, Lois Gilbert, Wayne L. Gold, Maria Major, Tony Mazzulli, Samira Mubareka, Jelena Vojcic, Jingyan Yang, Pingping Zhang, Catherine Martin, Moe H. Kyaw...

Citation: BMC Infectious Diseases 2025 25:194

Content type: Research Published on: 8 February 2025

#### **Perspectives of the COVID-19 pandemic and vaccination among racially and ethnically diverse gay, bisexual, and other men who have sex with men with and without HIV in the US South: findings from qualitative individual in-depth interviews**

*The impact of COVID-19 on specific populations, including gay, bisexual, and other men who have sex with men (GBMSM), varies based on a range of factors such as access to health care, underlying health behavior...*

Authors: Jake S. Waldman, Jorge Alonzo, Lilli Mann-Jackson, Sandy K. Aguilar-Palma, Manuel Garcia, Benjamin D. Smart and Scott D. Rhodes

Citation: BMC Infectious Diseases 2025 25:193

Content type: Research Published on: 8 February 2025

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 08 Feb 2025)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 08 Feb 2025)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 08 Feb 2025)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 08 Feb 2025)

**Classification of risk for transmission of vaccine-preventable diseases in Brazilian municipalities: comparative analysis before and after the national movement for vaccination and multivaccination proposed by the Ministry of Health as of 2023**

*To analyze the classification of the risk of transmission of vaccine-preventable diseases in Brazilian municipalities before and after the National Movement for Vaccination and Multivaccination proposed by the...*

Authors: Ana Catarina de Melo Araújo, Thales Philipe Rodrigues da Silva, Janaina Fonseca Almeida Souza, Krishna Mara Rodrigues Freire, Fernanda Penido Matozinhos and Eder Gatti Fernandes

Citation: *BMC Public Health* 2025 25:527

Content type: Research Published on: 8 February 2025

**Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national study**

*Although the second booster dose of COVID-19 vaccines is available, vaccine hesitancy among the public may have peaked due to the surge in infections caused by the Omicron variant. To improve coverage of the s...*

Authors: Xin Liu, You Xin, Ling Zhang, Yijin Wu, Shu Jing, Zhenwei Dai, Tianrui Ren, Xiaoyang Liu, Jiaqi Fu, Xu Chen, Weijun Xiao, Hao Wang, Yiman Huang, Wenjun Wang, Xiaofen Gu, Li Ma...

Citation: *BMC Public Health* 2025 25:503

Content type: Research Published on: 7 February 2025

**Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study**

*Human papillomavirus (HPV) infections are highly prevalent sexually transmitted infections, notably associated with various cancers. This study analyses the health and economic impacts of HPV-associated diseases...*

Authors: Vojtech Kamenský, Lukáš Dostálek, Martin Rožánek, Aleš Tichopád, Roman Prymula and Ivana Šarkanová

Citation: *BMC Public Health* 2025 25:481

Content type: Research Published on: 5 February 2025

**COVID-19 vaccine uptake in Zimbabwe and Sierra Leone: an application of Health Belief Model constructs**

*While African countries, in general, experienced a milder COVID-19 impact compared to Western nations, they faced challenges with vaccine uptake. Specifically, Zimbabwe and Sierra Leone saw vaccine acceptance ...*

Authors: Simon Ssentongo, Alex Muhereza, Morie Mustapha, Ruth Gemi, Dennis Cherian, Rebecca Waugh, Benjamin Crookston, Cougar Hall, Mary Linehan, Hayden Borg and Joshua West

Citation: *BMC Public Health* 2025 25:451

Content type: Research Published on: 4 February 2025

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 08 Feb 2025)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

February 2025 - Volume 30 - 1

<https://ebm.bmj.com/content/30/1>



[Reviewed earlier]

### **BMJ Global Health**

December 2024 - Volume 9 - 12

<https://gh.bmj.com/content/9/12>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 103, Number 1, January 2025, 1-80

<https://www.who.int/publications/journals/bulletin/>

#### **[In this month's Bulletin](#)**

In the editorial section, Katherine Littler et al. (2) call for papers for a special theme issue on the ethics of research into health and climate change.

Gary Humphreys (5–6) reports on initiatives to mitigate unintended consequences of health policies. Glenda Gray talks to Humphreys (7–8) about her career working on HIV prevention and treatment.

[Reviewed earlier]

### **Cell**

Feb 06, 2025 Volume 188 Issue 3 p573-868

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

### **Child Care, Health and Development**

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 2 Pages: 311-598 February 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

February 2025 Volume 47 Issue 2 p115-178

<http://www.clinicaltherapeutics.com/current>

*Editorial*

#### **[Managed Entry Agreements: Tools of Necessity, Works in Progress](#)**

Paul Beninger

Published online: January 21, 2025

p115-116

*Reviews*

#### **[A Systematic Review of Challenges and Opportunities in the Implementation of Managed Entry Agreements for Advanced Therapy Medicinal Products](#)**

Andrea Greco, et al.

Published online: December 19, 2024 e16-e26 Open Access

### *Highlights*

- Managed Entry Agreements can be classified into 2 main categories: financial-based agreements (FBAs) and outcome-based agreements (OBAs).
- FBA offers short-term relief but may disincentivize investment in Advanced Therapy Medicinal Products (ATMPs).
- For ATMPs targeting rare conditions, limited biological knowledge complicates endpoint selection, prolonging uncertainties in spread payments and outcome-linked payments. Such selection becomes even more challenging when survival is not a driver.
- The fragmentation in the US health care system hinders OBAs, but a new Cell and Gene Therapy Access model enables direct negotiations with the Centers for Medicare & Medicaid Services, streamlining implementation.
- Although no specific challenges or opportunities related to particular types of ATMPs (gene therapy, cell therapy, or tissue-engineered-specific) were identified, some were exacerbated by the intrinsic nature of ATMPs.

### **Clinical Trials**

Volume 21 Issue 6, December 2024

<https://journals.sagepub.com/toc/ctja/21/6>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 08 Feb 2025]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 148 January 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/147/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 7, Issue 6 / December 2024

<https://www.liebertpub.com/toc/crispr/7/6>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 40, Issue 12 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 08 Feb 2025]

[No new digest content identified]

**Developing World Bioethics**

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

**Development Policy Review**

Volume 43, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

**EMBO Reports**

Volume 26 Issue 2 27 January 2025

<https://www.embopress.org/toc/14693178/current>

[New issue; No digest content identified]

**Emerging Infectious Diseases**

Volume 31, Number 1—January 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 46, Issue 6 Pages: 1-35 November–December 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Data monitoring committee insights / Ethics reviews and AI tools***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 34, Issue 6, December 2024

<https://academic.oup.com/eurpub/issue/34/6>

[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

*Special Section*

***Will Trump Change the World?***

### **Forum for Development Studies**

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 08 Feb 2025]

[No new digest content identified]

### **Gene Therapy – Nature**

Volume 32 Issue 1, January 2025

<https://www.nature.com/gt/volumes/32/issues/1>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 27, Issue 1 January 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/1>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 08 Feb 2025]

#### **[Digital twins as global learning health and disease models for preventive and personalized medicine](#)**

*Ineffective medication is a major healthcare problem causing significant patient suffering and economic costs. This issue stems from the complex nature of diseases, which involve altered interactions among tho...*

Authors: Xinxu Li, Joseph Loscalzo, A. K. M. Firoj Mahmud, Dina Mansour Aly, Andrey Rzhetsky, Marinka Zitnik and Mikael Benson

Citation: *Genome Medicine* 2025 17:11

Content type: Review Published on: 7 February 2025

### **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[New issue; No digest content identified]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)  
[Accessed 08 Feb 2025]  
[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 08 Feb 2025]  
[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 2, December 2024  
<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>  
***Special Section: Distress Migration and the Right to Health***  
[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024  
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
*Article*  
**[Pandemic preparedness and response: a new mechanism for expanding access to essential countermeasures](#)**  
Nicole Hassoun, Kaushik Basu, Lawrence Gostin  
Published online by Cambridge University Press:  
31 May 2024, pp. 474-497

### **Health Policy and Planning**

Volume 40, Issue 1, January 2025  
<https://academic.oup.com/heapol/issue/40/1>  
*Original Articles*  
**[Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines](#)**  
Rupali J Limaye and others  
*Health Policy and Planning*, Volume 40, Issue 1, January 2025, Pages 23–30,  
<https://doi.org/10.1093/heapol/czae059>

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>  
[Accessed 08 Feb 2025]  
[No new digest content identified]

## **Human Gene Therapy**

Volume 36, Issue 1-2 / January 2025

<https://www.liebertpub.com/toc/hum/36/1-2>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

## **Immunity**

Jan 14, 2025 Volume 58 Issue 1 p1-264

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 08 Feb 2025]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 08 Feb 2025]

### **Environmental, socioeconomic, and sociocultural drivers of monkeypox transmission in the Democratic Republic of the Congo: a One Health perspective**

*Monkeypox (mpox) is an emerging zoonotic disease that has persistently impacted public health in endemic regions of West and Central Africa for over half a century. The Democratic Republic of the Congo (DRC) r...*

Authors: Guangyu Lu, Zeyin Chong, Enyu Xu, Ce Na, Kaixuan Liu, Liying Chai, Pengpeng Xia, Kai Yang, Guoqiang Zhu, Jinkou Zhao and Olaf Müller

Citation: *Infectious Diseases of Poverty* 2025 14:7

Content type: Research Article Published on: 7 February 2025

### **Machine learning for predicting severe dengue in Puerto Rico**

*Distinguishing between non-severe and severe dengue is crucial for timely intervention and reducing morbidity and mortality. World Health Organization (WHO)-recommended warning signs offer a practical approach...*

Authors: Zachary J. Madewell, Dania M. Rodriguez, Maile B. Thayer, Vanessa Rivera-Amill, Gabriela Paz-Bailey, Laura E. Adams and Joshua M. Wong

Citation: Infectious Diseases of Poverty 2025 14:5  
Content type: Research Article Published on: 4 February 2025

### **International Health**

Volume 17, Issue 1, January 2025  
<https://academic.oup.com/inthealth/issue/17/1>  
[Reviewed earlier]

### **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)  
<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>  
[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 1 (2025): January 2025  
<https://www.ijcmph.com/index.php/ijcmph/issue/view/120>  
<https://academic.oup.com/ije/issue/53/6>  
[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 53, Issue 6, December 2024  
<https://academic.oup.com/ije/issue/53/6>  
[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024  
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>  
*Table of contents*  
[Reviewed earlier]

### **JAMA**

February 4, 2025, Vol 333, No. 5, Pages 361-442  
<https://jamanetwork.com/journals/jama/currentissue>  
*Research Letter*

#### **[Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons](#)**

Andrew H. Karaba, MD, PhD; Camille Hage, MD; Isabella Sengsouk, BS; et al.  
JAMA. 2025;333(5):429-432. doi:10.1001/jama.2024.25395

This prospective study investigates antibody response following respiratory syncytial virus vaccination in immunocompromised individuals.

### **JAMA Health Forum**

January 2025, Vol 6, No. 1  
<https://jamanetwork.com/journals/jama-health-forum/issue>  
[Reviewed earlier]



**JAMA Pediatrics**

January 2025, Vol 179, No. 1, Pages 3-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

**JBİ Evidence Synthesis**

January 2025 - Volume 23 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

**Journal of Adolescent Health**

January 2025 Volume 76 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

**Journal of Community Health**

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[New issue; No digest content identified]

**Journal of Development Economics**

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

December 2024 - Volume 78 - 12

<https://jech.bmj.com/content/78/12>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 17, Issue 4 Pages: 689-873 December 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: 20th Anniversary Forum***

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 26, Issue 6 December 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-6>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 37, Issue 1 Pages: 1-349 January 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

February 2025 - Volume 51 - 2

<http://jme.bmj.com/content/current>

*Original research*

**[No-fault compensation schemes for COVID-19 vaccine injury: a mixed bag for claimants and citizens](#)** (18 June, 2024)

Sonia Macleod, Francesca Uberti, Enga Kameni

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 275 December 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/275/suppl/C>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

February 2025 Volume 22 Issue 223

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

**Journal of Travel Medicine**

Volume 32, Issue 1, January 2025

<https://academic.oup.com/jtm/issue>

[New issue; No digest content identified]

**Journal of Virology**

Volume 98 Number 12 December 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Feb 08, 2025 Volume 405 Number 10477 p439-516  
<https://www.thelancet.com/journals/lancet/issue/current>  
*Editorial*

**American chaos: standing up for health and medicine**

The Lancet

*Comment*

**Announcing the *Lancet* Commission on US Societal Resilience in a Global Pandemic Age: Lessons for the Present from the Future**

Elijah Aronoff-Spencer, Richard M Carpiano, Lara Vojnov on behalf of the Lancet Commission on US Societal Resilience in a Global Pandemic Age: Lessons for the Present from the Future

*Viewpoint*

**Global health partnerships for a post-2030 agenda**

Antoine de Bengy Puyvallée, et al.

**The Lancet Child & Adolescent Health**

Jan 2025 Volume 9 Number 1 p1-76  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

**Lancet Digital Health**

Jan 2025 Volume 7 Number 1 e1-e102  
<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

**Lancet Global Health**

Jan 2025 Volume 13 Number 1 e1-e171  
<https://www.thelancet.com/journals/langlo/issue/current>  
[Reviewed earlier]

**Lancet Infectious Diseases**

Jan 2025 Volume 25 Number 1 p1-134, e1-e59  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

**Lancet Public Health**

Jan 2025 Volume 10 Number 1 e1-e70  
<https://www.thelancet.com/journals/lanpub/issue/current>  
[Reviewed earlier]

**Lancet Respiratory Medicine**

Jan 2025 Volume 13 Number 1 p1-100, e1-e8  
<https://www.thelancet.com/journals/lanres/issue/current>  
[Reviewed earlier]

## **Maternal and Child Health Journal**

Volume 28, Issue 12 December 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-12>

[Reviewed earlier]

## **Medical Decision Making (MDM)**

Volume 45 Issue 1, January 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Molecular Therapy**

Feb 05, 2025 Volume 33 Issue 2 p423-824

<https://www.cell.com/molecular-therapy/current>

*Editorials*

### **[RNA and epigenetic editing: The new frontier in gene and cell therapy](#)**

Federico Avila-Moreno, Paloma H. Giangrande

Over the past two decades, the field of gene and cell therapy has been revolutionized by the advent of CRISPR-Cas9 genome editing.<sup>1,2</sup> This technology has concomitantly driven the meteoric rise of the study of epigenetic and RNA editing, including m6A RNA methylation, m6A epitranscriptomics, and RNA-based editing methods. Indeed, thousands of articles focused on these topics, with a significant “explosive” increase of the RNA-based editing methods, have been published in the last 12 years

### **[In this issue](#)**

Despite the success of mRNA vaccines during the COVID-19 pandemic, these vaccines are limited by the short half-life of mRNA and transient expression of the gene of interest, necessitating multiple boosters to achieve sustained immunity. By contrast, self-amplifying RNA (saRNA) vaccines provide extended expression of the gene of interest and have dose-sparing capacity. Alphaviral saRNA vectors, in particular, show enhanced humoral and cellular immunogenicity against the SARS-CoV-2 antigen in mice and high transgene expression in human skin explants.

## **Nature**

Volume 638 Issue 8049, 6 February 2025

<https://www.nature.com/nature/volumes/637/issues/8049>

*Editorial* 05 Feb 2025

### **[Out of Africa: celebrating 100 years of human-origins research](#)**

A landmark study reporting the discovery of *Australopithecus africanus* one century ago put the African continent at the centre of the story of humanity.

*Editorial* 04 Feb 2025

### **[How the World Health Organization can thrive without the United States](#)**

If the 193 remaining member nations want the WHO to succeed, they must find a way to pay for it.

*World View* 04 Feb 2025

**'Despair is not an option' — how scientists can help protect federal research**

Government scientists in the US must be clear-eyed and continue to serve the public.

Gretchen T. Goldman

**Nature Biotechnology**

Volume 43 Issue 1, January 2025

<https://www.nature.com/nbt/volumes/43/issues/1>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 08 Feb 2025)

[Reviewed earlier]

**Nature Genetics**

Volume 57 Issue 1, January 2025

<https://www.nature.com/ng/volumes/57/issues/1>

[Reviewed earlier]

**Nature Human Behaviour**

Volume 9 Issue 1, January 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/1>

[Reviewed earlier]

**Nature Medicine**

Volume 31 Issue 1, January 2025

<https://www.nature.com/nm/volumes/31/issues/1>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 24 Issue 1, January 2025

<https://www.nature.com/nrd/volumes/24/issues/1>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 26 Issue 1, January 2025

<https://www.nature.com/nrg/volumes/26/issues/1>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 25 Issue 1, January 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[New issue; No digest content identified]

### **New England Journal of Medicine**

Volume 392 No. 6 February 6, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

#### **Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries**

J.S. Ross

*Abstract*

State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements between Medicaid programs and manufacturers of gene therapies for sickle cell disease.

### **NEJM Evidence**

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[New issue; No digest content identified]

### **npj Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 08 Feb 2025]

[No new digest content identified]

### **Pediatrics**

Volume 155, Issue 2 February 2025

<https://publications.aap.org/pediatrics/issue/155/2>

*Articles*

#### **Invalid Vaccine Doses Among Children Aged 0 to 35 Months: 2011 to 2020**

Alexandria N. Albers, MPH,

#### **A Bundled, Practice-Based Intervention to Increase HPV Vaccination**

Peter G. Szilagyi, MD, MPH; Alexander G. Fiks, MD, MSCE; Cynthia M. Rand, MD, MPH; Mary Kate Kelly, MPH; A. Russell Localio, PhD ...

*From the American Academy of Pediatrics*

*Policy Statement*

#### **Recommended Childhood and Adolescent Immunization Schedule: United States, 2025: Policy Statement**

Committee on Infectious Diseases

*Policy Statement*

#### **Environmental Issues in Global Pediatric Health: Policy Statement**

Lauren Zajac, MD, MPH, FAAP; Philip J. Landrigan, MD, MSc, FAAP; and the Council on Environmental Health and Climate Change

*Technical Report*

**Environmental Issues in Global Pediatric Health: Technical Report**

Lauren Zajac, MD, MPH, FAAP; Philip J. Landrigan, MD, MSc, FAAP; and the COUNCIL ON ENVIRONMENTAL HEALTH AND CLIMATE CHANGE

**PharmacoEconomics**

Volume 43, Issue 1 January 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-1>

[Reviewed earlier]

**PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 08 Feb 2025)

[No new digest content identified]

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 08 Feb 2025)

[No new digest content identified]

**PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)  
(Accessed 08 Feb 2025)

**Pathways and processes to adopting or switching to a single-dose HPV vaccination schedule in low- and middle-income countries: a qualitative study**

Sunny Roy, Megan D. Wyson, Erica N. Rosser, Ishani Sheth, Casey Geddes, Rupali J. Limaye, Joseph G. Rosen

Research Article | published 05 Feb 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004245>

**PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 08 Feb 2025)

**Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study**

Lin Geng, Lilith K. Whittles, Borame L. Dickens, Martin T. W. Chio, Yihao Chen, Rayner Kay Jin Tan, Azra Ghani, Jue Tao Lim

Research Article | published 07 Feb 2025 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004521>

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 08 Feb 2025)

[No new digest content identified]



## **PLoS One**

<http://www.plosone.org/>

[Accessed 08 Feb 2025]

### **[Navigating vaccination in pregnancy: Qualitative study in 21 ethnically diverse pregnant women](#)**

Mohammad S. Razai, Michael Ussher, Lucy Goldsmith, Sally Hargreaves, Pippa Oakeshott

Research Article | published 31 Jan 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0310823>

## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 08 Feb 2025]

[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

February 11, 2025 | vol. 122 | no. 6

<https://www.pnas.org/toc/pnas/122/6>

[New issue; No digest content identified]

## **PNAS Nexus**

Volume 4, Issue 1, January 2025

<https://academic.oup.com/pnasnexus/issue/4/1>

[Reviewed earlier]

## **Prehospital & Disaster Medicine**

Volume 39 - Issue 4 - August 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 191 February 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

February 2025 Volume 292 Issue 2040

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

## **Public Health**

Volume 238 Pages 1-316 (January 2025)

<https://www.sciencedirect.com/journal/public-health/vol/238/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

**Public Health Reports**

Volume 139 Issue 6, November/December 2024

<https://journals.sagepub.com/toc/phrg/139/6>

[Reviewed earlier]

**Qualitative Health Research**

Volume 35 Issue 1, January 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

**Research Ethics**

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 08 Feb 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

**Risk Analysis**

Volume 45, Issue 1 Pages: 1-263 January 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 08 Feb 2025]  
[No new digest content identified]

## **Royal Society Open Science**

January 2025 Volume 12 Issue 1

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

## **Science**

Volume 387| Issue 6733| 31 Jan 2025

<https://www.science.org/toc/science/current>

*Editorial*

### **Keeping our eye on the ball**

BY Willie E. May

*Editorial*

### **A world less safe and secure**

Lawrence O. Gostin and Benjamin Mason Meier

On 20 January, President Trump announced the withdrawal of the United States from the World Health Organization (WHO). President Trump shares many of the same concerns about WHO as previous administrations, including improved transparency, financial oversight, and accountability. He also believes that China has exerted undue influence on WHO—a charge that WHO adamantly denies. But the US cannot influence WHO if it is not at the table. WHO will remain at the center of global health governance, but this withdrawal will limit US leadership to protect public health and challenge WHO coordination in facing global challenges.

The US was central to the creation of WHO and has been its most influential member for over 75 years. US leadership has been foundational to WHO's achievements, from the eradication of smallpox and ongoing polio eradication initiative to its health-for-all strategy. As WHO's largest state funder, the US provides 22% of WHO's assessed contributions, alongside funds earmarked to US priorities, including HIV/AIDS and health emergencies.

Yet, when the US joined WHO in 1948, a joint resolution of Congress gave it the "right to withdraw from the Organization on a 1-year notice." Withdrawing from WHO now will forfeit US voting power and political leadership at the World Health Assembly, the WHO decision-making body, severely reducing its ability to set the world's health agenda, defend fundamental US interests, and advance crucial WHO reforms. The US will be on the outside looking in while the most consequential decisions are taken, including the adoption of a new Pandemic Agreement and the election of the next director-general in 2027. As global norms are set and scientific standards issued, the absence of the US will undermine scientific research, health security, and foreign policy.

The US benefits from WHO collaborations to advance scientific research. Seventy-one WHO Collaborating Centers are based in the US, including 18 at the Centers for Disease Control and Prevention. Withdrawing from WHO will limit domestic public health agencies and the US pharmaceutical industry, which rely on access to disease surveillance, pathogen samples, and genomic data through a vast network of WHO laboratories and other partners. As the US faces a major H5N1 influenza outbreak in livestock, US scientists would have reduced access to WHO's Global Influenza Surveillance and Response System to develop lifesaving countermeasures against H5N1 and ensure seasonal influenza vaccines.

WHO membership provides extensive networks to support US health security, safeguarding American lives and economic growth. WHO's Global Outbreak Alert and Response Network provides real-time data on novel outbreaks needed for early detection and response. The US has long looked to WHO to strengthen alliances and advance its national interests. If the US becomes the only major country outside WHO, allies would view America as an unreliable partner. It would feed a subversive narrative that the US is not a genuine partner with the Global South and weaken US diplomacy throughout the world.

Absent US funding and leadership, WHO could be severely weakened, making every country less healthy and safe. The agency's budget gap will be roughly \$3.3 billion, with no state likely to compensate for that funding gap. Loss of US support will diminish WHO's ability to identify, report, and respond to public health emergencies. Much of WHO's work is unseen but critically important, including technical assistance, standard setting, and advocacy for evidence-based policies.

Within the World Health Assembly, new power structures and alliances will emerge that may shift key WHO policies important to the US in preparing for future pandemics, including the 2024 amendments to the International Health Regulations and a new Pandemic Agreement. Advancing US health priorities outside of WHO cannot compensate for being at the table in the world's premier health agency.

WHO without US leadership may give rise to a new global health order, where the loss of WHO authority will push other nations toward bilateral initiatives that advance national geopolitical priorities. This fractured global health ecosystem will undermine international cooperation and global solidarity necessary to respond to health threats that transcend national boundaries. It will also make it far more difficult to ensure equitable access to lifesaving medical resources—an important lesson from the COVID-19 pandemic. Without US leadership, this new multipolar governance landscape will reshape the very meaning of global health, challenging a divided world as it faces future health challenges.

*Feature*

### **[In the cradle of cholera](#)**

BY Martin Enserink

06 Feb 2025: 572-577

Bangladesh is leading the fight against this ancient scourge, and vaccine researcher Firdausi Qadri is on the front lines

### **Science and Engineering Ethics**

Volume 31, Issue 1 February 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 17| Issue 784| 5 Feb 2025

<https://www.science.org/toc/stm/current>

*Reports*

### **[Selection and prioritization of candidate combination regimens for the treatment of tuberculosis](#)**

BY Natasha Strydom, et al.

05 Feb 2025

Mathematical modeling of relapse data predicts tuberculosis drug regimens, identifying short, potential combinations for clinical trials.

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 08 Feb 2025]

[No new digest content identified]

### **Social Science & Medicine**

Volume 364 January 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 08 Feb 2025]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 63 January–February 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 30, Issue 2 Pages: i-iv, 71-142 February 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

### **Vaccine**

Volume 47 15 February 2025

<https://www.sciencedirect.com/journal/vaccine/vol/47/suppl/C>

[Reviewed earlier]

### **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 08 Feb 2025]

*Open Access Article*

**[Measles Vaccination Coverage and Anti-Measles Herd Immunity Levels in the World and WHO Regions Worsened from 2019 to 2023](#)**

by Pedro Plans-Rubió

Vaccines 2025, 13(2), 157; <https://doi.org/10.3390/vaccines13020157> - 5 Feb 2025

*Abstract*

Objectives: The objectives of this study were as follows: to determine mean percentages of measles vaccination coverage with zero, one and two doses of vaccine and anti-measles herd immunity levels in World Health Organization (WHO) regions in 2023; to assess variations in measles [...]

## Value in Health

February 2025 Volume 28 Issue 2 p175-322

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

## World Development

Volume 185 January 2025

<https://www.sciencedirect.com/journal/world-development/vol/184/suppl/C>

[Reviewed earlier]

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

## ***Pre-Print Servers***

### **arxiv**

<https://arxiv.org/>

[Accessed 08 Feb 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2501.19405 (cross-list from cs.HC) [pdf, html, other]

### **Human-Precision Medicine Interaction: Public Perceptions of Polygenic Risk Score for Genetic Health Prediction**

Yuhao Sun, Albert Tenesa, John Vines

Precision Medicine (PM) transforms the traditional "one-drug-fits-all" paradigm by customising treatments based on individual characteristics, and is an emerging topic for HCI research on digital health. A key element of PM, the Polygenic Risk Score (PRS), uses genetic data to predict an individual's disease risk. Despite its potential, PRS faces barriers to adoption, such as data inclusivity, psychological impact, and public trust. We conducted a mixed-methods study to explore how people perceive PRS, formed of surveys (n=254) and interviews (n=11) with UK-based participants. The interviews were supplemented by interactive storyboards with the ContraVision technique to provoke deeper reflection and discussion. We identified ten key barriers and five themes to PRS adoption and proposed design implications for a responsible PRS framework. To address the complexities of PRS and enhance broader PM practices, we introduce the term Human-Precision Medicine Interaction (HPMI), which integrates, adapts, and extends HCI approaches to better meet these challenges.

arXiv:2502.00071 (cross-list from physics.soc-ph) [pdf, html, other]

### **Including frameworks of public health ethics in computational modelling of infectious disease interventions**

Alexander E. Zarebski, Nefel Tellioglu, Jessica E. Stockdale, Julie A. Spencer, Wasiur R. KhudaBukhsh, Joel C. Miller, Cameron Zachreson

Decisions on public health interventions to control infectious disease are often informed by computational models. Interpreting the predicted outcomes of a public health decision requires not only high-quality modelling, but also an ethical framework for assessing the benefits and harms associated with different options. The design and specification of ethical frameworks matured independently of computational modelling, so many values recognised as important for ethical decision-making are missing from computational models. We demonstrate a proof-of-concept approach to incorporate multiple public health values into the evaluation of a simple computational model for vaccination against a pathogen such as SARS-CoV-2. By examining a bounded space of alternative prioritisations of values (outcome equity and aggregate benefit) we identify value trade-offs, where the outcomes of optimal strategies differ depending on the ethical framework. This work demonstrates an approach to incorporating diverse values into decision criteria used to evaluate outcomes of models of infectious disease interventions.

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 08 Feb 2025]

[No new digest content identified]

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 08 Feb 2025]

[Filter: All articles]

### **AVERTED MORTALITY BY COVID-19 VACCINATION IN BELGIUM BETWEEN 2021 AND 2023**

Veerle Stouten, Izaak Van Evercooren, Catharina Vernemmen, Toon Braeye, Lucy Catteau, Mathieu Roelants, Matthieu Billuart, Thoman Lamot, Natalia Bustos Sierra, Naïma Hammami, Elias Vermeiren, Angel Rosas, Koen Blot, Anna I. Schmelz, Léonore Nasiadka, Serge Nganda, Joris A.F. van Loenhout  
medRxiv 2025.02.06.25321208; doi: <https://doi.org/10.1101/2025.02.06.25321208>

### **An Implementation Science Framework to Understand Low Coverage in Mass Dog Rabies Vaccination**

Ricardo Castillo-Neyra, Lizzie Ortiz-Cam, Jorge L. Cañari-Casaño, Elvis W. Diaz, Laura D. Tamayo, Guillermo Porras, Sergio E. Recuenco, Valerie A. Paz-Soldan  
medRxiv 2025.02.05.25321168; doi: <https://doi.org/10.1101/2025.02.05.25321168>

### **Estimating the impact of decreasing vaccination response times for outbreaks in low- and middle-income countries**

Dominic Delport, Alina M. Muellenmeister, Jane Greig, Romesh Gerald Abey Suriya, Nick Scott  
medRxiv 2025.02.04.25321698; doi: <https://doi.org/10.1101/2025.02.04.25321698>

### **Mpox Knowledge, Risk Perception, Attitudes and Willingness to Vaccinate in Colombia's LGBTIQ+ Communities: Online Survey (CoSex)**

Cándida Diaz-Brochero, Miguel Barriga, John Fredy Ramirez, David Santiago Quevedo, Geraldine Gomez, Juliana Mateus, Natalia Nino-Machado, Juliana Cuervo-Rojas, Zulma M. Cucunubá  
medRxiv 2025.02.03.25321611; doi: <https://doi.org/10.1101/2025.02.03.25321611>

**Vaccine Hesitancy, Coercion and Regret: Post-Pandemic Lessons on COVID-19 Vaccine Policies and Outreach among Newcomer Communities in Alberta, Canada**

Minnella Antonio, Edna Ramirez-Cerino, Adanech Sahilie, Mussie Yemane, Michael Youssef, Ingrid Nielssen, Linda Holdbrook, Mohammad Yasir Essar, Maria Santana, Denise Spitzer, Kevin Pottie, Gabriel E. Fabreau

medRxiv 2025.02.03.25320914; doi: <https://doi.org/10.1101/2025.02.03.25320914>

**Evolution of Pandemic Cholera at its Global Source**

Amber Barton, Mokibul Hassan Afrad, Alyce Taylor-Brown, Nisha Singh, Chetan Thakur, Taufiqul Islam, Sadia Isfat Ara Rahman, Marjahan Akhtar, Yasmin Ara Begum, Taufiqur Rahman Bhuiyan, Ashraful Islam Khan, Neelam Taneja, Nicholas R. Thomson, Firdausi Qadri

medRxiv 2025.02.03.25321585; doi: <https://doi.org/10.1101/2025.02.03.25321585>

**Defining drivers of human papillomavirus (HPV) vaccine uptake in migrant populations globally and strategies and interventions to improve coverage: a systematic review**

Michiyo Iwami, Oumnia Bouaddi, Mohammad S Razai, Rania Mansour, Beatriz Morais, Nafeesa Mat Ali, Alison F Crawshaw, Sainabou Bojang, Farah Seedat, Anna Deal, Sophie Webb, Jessica Carter, Nathaniel Aspray, Nuria Sanchez Clemente, Juan Arroyo-Laguna, Sanjeev Krishna, Yolanda Augustin, Henry M Staines, Sally Hargreaves

medRxiv 2025.01.31.25321303; doi: <https://doi.org/10.1101/2025.01.31.25321303>

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]*

*[No new digest content identified]*

**Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

*[Accessed 08 Feb 2025]*

*Research Article Open Access*

**REVISED - A pilot study to explore utility of electronic informed consent in a low- income setting; the case of a Controlled human infection study in Blantyre, Malawi**

*[version 2; peer review: 4 approved with reservations]*

Clara Ngoliwa\*

Electronic informed consent can improve accuracy, workflow, and overall patient experience in clinical research but has not been used in Malawi, owing to uncertainty about availability, utility, patient data security and technical support.

\*

\*

\*

\*

**Think Tanks**

**Brookings** [to 08 Feb 2025]

<http://www.brookings.edu/>

*Reports, Events*

*No new digest content identified.*

**Center for Global Development** [to 08 Feb 2025]



<https://www.cgdev.org/>

*All Research*

*CGD NOTES*

**[A New Compact for Health Financing: Insights from Policymakers Across Africa](#)**

Anastassia Demeshko et al.

February 07, 2025

The political economy of global health financing is increasingly driven by fiscal constraints, geopolitical instability, and shifting power dynamics. The COVID-19 pandemic stalled or reversed health gains, and countries and donors now face tightening budgets and rising debt repayments, threatening t...

*WORKING PAPERS*

**[It's All Fun and Games? The Persistent Treatment Effects of Willingness-to-Pay Experiments](#)**

Jenny C. Aker et al.

February 05, 2025

Willingness-to-pay (WTP) experiments have been widely used to assess demand for a variety of products. Do they also generate persistent treatment effects? We answer this question using a randomized controlled trial of a baseline WTP experiment, combined with in-person and phone survey data over a fo...

**Chatham House** [to 08 Feb 2025]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 08 Feb 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 08 Feb 2025]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 08 Feb 2025]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 08 Feb 2025]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 08 Feb 2025]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 08 Feb 2025]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 08 Feb 2025]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Research Feb 7, 2025*

### **A Call for Community-Shared Decisions**

In light of issues such as antibiotic overuse and prescription opioid misuse, the authors present recommendations for medical decision-making that includes the community as well as the patient and clinician in order to maximize collective benefit.

*Research Summary Feb 6, 2025*

### **Federal Funding Recommendations to Scale Up Evidence-Based Practices in Health and Social Services**

The brief summarizes seven policy recommendations to optimize federal spending on large-scale implementation of evidence-based practices in health and social services, identified through focus groups with officials, and real-world examples of each.

**Urban Institute** [to 08 Feb 2025]

<https://www.urban.org/publications>

### **New Research Publications - Selected**

*Fact Sheet*

### **Government Grants and Contracts for Nonprofits in 2023: Data Tables from the Nonprofit Trends and Impacts Study**

*February 7, 2025*

In 2023, two-thirds of nonprofits from a nationally representative panel study in the United States received at least one government grant or contract, resulting in the average nonprofit generating one-quarter of its revenue from government sources that year. Over a third of nonprofits received more than a quarter of their revenue from the government, and about two in ten nonprofits received more than half of their revenue from the government.

**World Economic Forum** [to 08 Feb 2025]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*  
\* \* \* \*